Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 16/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 16/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TLR3 | O15455 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523641 | 0.83 | HIF1A (0.53) | HIF1AEPAS1TLR3 | |
| SCHEMBL9032078 | 0.83 | HIF1A (0.53) | HIF1AEPAS1COXFA4 | |
| SCHEMBL507142 | 0.83 | HIF1A (0.53) | HIF1AEPAS1TLR3 | |
| SCHEMBL5808068 | 0.83 | HIF1A (0.48) | HIF1AEPAS1PTGS1PTGS2XDH | |
| SCHEMBL2825117 | 0.81 | HIF1A (0.52) | HIF1AEPAS1COXFA4ALDH1A1CYP3A4 | |
| SCHEMBL14930293 | 0.81 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL27666053 | 0.80 | HIF1A (0.54) | HIF1AEPAS1COXFA4ALDH1A1CYP3A4 | |
| SCHEMBL14541294 | 0.80 | HIF1A (0.56) | HIF1AEPAS1 | |
| SCHEMBL27665986 | 0.79 | COXFA4 (0.57) | HIF1AEPAS1COXFA4ALDH1A1CYP3A4 | |
| SCHEMBL16011616 | 0.78 | HIF1A (0.54) | HIF1AEPAS1COXFA4TLR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| EP-0453837-B1 | Substituted pyridazinones, process for their preparation and their use as parasiticide | BAYER AG (DE) | 1996-06-19 | — | — | EP | disclosed |
| US-5141939-A | PESTICIDAL CHROMEN-6-YL-METHYL-OXY-AND-THIAPYRIZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-25 | — | — | US | disclosed |
| EP-0453837-A2 | Substituted pyridazinones, process for their preparation and their use as parasiticide | BAYER AG (DE) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | HIF1A 6/4885EPAS1 72/4885PTGS1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.